Home > News > Nanotechnology Investment and Commercialization Forum
September 9th, 2004
Nanotechnology Investment and Commercialization Forum
This forum is a networking event where Investors, Researchers and Entrepreneurs will be exposed to presentations and displays which show critical stages of the value chain of new venture creation in various nanotechnology domains.
NICF: Nanotechnology Value Chains, Focus on Biotechnology and Pharmaceutical Ventures
Nanotechnology Investment and Commercialization Forum.
The Nanotechnology Value Chain: IP to IPO.
DATE: September 29
PLACE: SRI Auditorium . 333 Ravenswood Ave. Menlo Park, CA
TIME: 9 a.m. registration, 10AM – 6PM
MISSION: This forum is a networking event where Investors, Researchers and
Entrepreneurs will be exposed to presentations and displays which show critical
stages of the value chain of new venture creation in various nanotechnology domains.
Speakers will include:
- Dr. Sam Doctors, ACET
- Dr. Regis Kelley, UCSF, QB3 and CBE
- Dr. Micheal Mueller, UC Discovery Grant Organization:
- Dr. Jeff Rosner, Agilent
- Richard Trecartin, Dorsey and Whitney LLP
- Dr. Alexei Andreev, Draper Fisher and Jurvetson
10 AM - 5 PM:
Registration 9:00 a.m.
Morning Session 10 a.m. - 12 a.m.
12 a.m. - 1 p.m. Lunch (included)
Afternoon Session 1 p.m. - 4 p.m
Reception and Networking 4 p.m. - 5 p.m.
ACET, the Alameda Center for Environmental Technologies, is a business incubator helping environmental and biotech start-ups grow and prosper in the San Francisco Bay Area. ACET offers an outstanding location, expert business resources, and links to technology, expertise, and markets at home and abroad.
About UC Discovery Grants
The Industry-University Cooperative Research Program (IUCRP) awards MICRO Grants and UC Discovery Grants in five fields of science and engineering. UC Discovery Grants form a 3-way partnership between UC, Industry Sponsors, and the State of California.
During the last half-century, molecular genetics revolutionized biomedical research and gave rise to the biotechnology industry. During the next half-century, the application of the quantitative sciences - mathematics, physics, chemistry and engineering - to biomedical research brings about a second revolution that promises to improve human health and create dynamic new technologies.
To catalyze these changes, the California Institute for Quantitative Biomedical Research (QB3), a cooperative effort among three campuses of the University of California and private industry, harnesses the quantitative sciences to integrate our understanding of biological systems at all levels of complexity - from atoms and protein molecules to cells, tissues, organs and the entire organism. This long-sought integration allows scientists to attack problems that have been simply unapproachable before, setting the stage for fundamental new discoveries, new products and new technologies for the benefit of human health.
The Center for BioEntrepreneurship has developed programs and activities that are creating the next generation of leaders in life science entrepreneurship and industry, and that weave the University community into the wider fabric of leading companies, financiers and professionals necessary for the successful migration of discoveries from the laboratory to commercialization for the benefit of the institution and society.
Agilent delivers innovative technologies, solutions and services to a wide range of customers in communications, electronics, life sciences and chemical analysis. The breadth and depth of our expertise enable us to offer solutions across our customers' entire product life cycle from research and development to manufacturing to installation and management. With insight gained from this unique and comprehensive perspective, we can help our customers get the best products and services to market quickly and profitably.
About Draper Fisher Jurvetson
Draper Fisher Jurvetson is the premier early stage venture capital firm. Founded in 1985, Draper Fisher Jurvetson has created a global network of affiliated venture funds with approximately $3 billion in capital commitments and offices in the major technology centers around the world. Headquartered in Silicon Valley, the firm has proven expertise in identifying and helping extraordinary entrepreneurs who want to change the world.
Copyright nanoSIG. Reprinted with permission.
If you have a comment, please
A first glimpse inside a macroscopic quantum state March 28th, 2015
DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015
Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015
Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015